PD-L1 expression has been identified as a significant independent predictive biomarker of ICIs effectiveness across multiple cancer types, such as breast cancer, NSCLC, urothelial carcinoma, and hepatocellular carcinoma (23–25). The gene discussed is CD274; the disease is hepatocellular carcinoma.